Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.

Best practice & research. Clinical gastroenterology - 1 Aug 2012

Esteban Rafael, Buti Maria

Abstract excerpt

Boceprevir and telaprevir are the first two protease inhibitors available for the treatment of patients infected with HCV genotype 1. In treatment naïve patients, a sustained virologic response (SVR) of 70-80% is observed when either of these protease inhibitors is used with peginterferon and ribavirin A rapid virologic response (RVR) is observed in 56-60% of them allowing a shorter course of 24-28 weeks of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Interferon-alpha

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 23199503
DOI: 10.1016/j.bpg.2012.09.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.PMID 23199503Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.Semantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.Semantic proximity Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.Semantic proximity Read ↗

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Semantic proximity Read ↗

Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.Semantic proximity Read ↗

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.Semantic proximity Read ↗

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.Semantic proximity Read ↗

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.